SCYX Q4 2022 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2M+155.3% YoY

Gross Profit

$1M87.1% margin

Operating Income

-$22M-1475.1% margin

Net Income

-$14M-946.8% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

-2.1%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$454,000

Balance Sheet

Total Assets

$88M

Total Liabilities

$85M

Stockholders' Equity

$3M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$597,000	+155.3%
Gross Profit	$1M	$430,000	+208.8%
Operating Income	-$22M	-$22M	-0.8%
Net Income	-$14M	-$29M	+50.7%

Revenue Segments

Product

$1M100%